Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.55−0.30 (-2.76%)
Close on Nov 20, 2026Market cap $2.30BP/E –Yield –
Neogen free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Neogen's free cash flow for the twelve months ending Aug 31, 2026 was $49.80M. For fiscal 2026 it was $31.90M. Over ten years it grew 4.2% a year on average. The highest annual figure on record is $61.83M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $31.90M | – |
| FY2025 | May 31, 2025 | -$46.40M | – |
| FY2024 | May 31, 2024 | -$76.10M | – |
| FY2023 | May 31, 2023 | -$24.73M | -156.7% |
| FY2022 | May 31, 2022 | $43.61M | -19.8% |
| FY2021 | May 31, 2021 | $54.38M | -12.0% |
| FY2020 | May 31, 2020 | $61.83M | +25.7% |
| FY2019 | May 31, 2019 | $49.18M | +2.1% |
| FY2018 | May 31, 2018 | $48.19M | +5.4% |
| FY2017 | May 31, 2017 | $45.70M | +116.5% |
| FY2016 | May 31, 2016 | $21.11M | -38.2% |
| FY2015 | May 31, 2015 | $34.17M | +237.5% |
| FY2014 | May 31, 2014 | $10.13M | -42.7% |
| FY2013 | May 31, 2013 | $17.66M | +79.1% |
| FY2012 | May 31, 2012 | $9.86M | -53.1% |
| FY2011 | May 31, 2011 | $21.05M | -6.7% |
| FY2010 | May 31, 2010 | $22.56M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $4.70M | – |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $26.20M | +8633.3% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $11.07M | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $7.83M | -66.1% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | -$13.20M | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $300.00K | -88.2% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$13.45M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $23.10M | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$56.35M | – |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $2.55M | -96.1% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$62.33M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$8.70M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$7.62M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $65.46M | +733.7% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$32.22M | – |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$30.83M | -321.7% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$27.14M | -223.8% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $7.85M | -46.4% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -$65.00K | -102.0% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $13.91M | -10.5% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $21.92M | +4.9% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $14.65M | -18.1% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $3.30M | -79.7% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $15.55M | +49.3% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $20.89M | +21.1% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $17.90M | -1.1% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $16.26M | +211.2% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $10.42M | -11.0% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $17.25M | +21.8% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $18.09M | +1.0% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $5.23M | -60.7% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $11.70M | +326.7% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $14.16M | -0.6% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $17.91M | +32.5% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $13.28M | +49.6% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $2.74M | -57.7% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $14.26M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $13.51M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $8.88M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $6.48M | – |
See a number that looks wrong?